Addressing the Measles-Mumps-Rubella Revaccination Guidelines for Allogenic Bone Marrow Transplant Patients: A Response to the American Society for Transplantation and Cellular Therapy 2019 Position Statement.

Biol Blood Marrow Transplant

Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California. Electronic address:

Published: July 2020

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.03.017DOI Listing

Publication Analysis

Top Keywords

addressing measles-mumps-rubella
4
measles-mumps-rubella revaccination
4
revaccination guidelines
4
guidelines allogenic
4
allogenic bone
4
bone marrow
4
marrow transplant
4
transplant patients
4
patients response
4
response american
4

Similar Publications

The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties: Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age. As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age. Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10-12 years of age.

View Article and Find Full Text PDF

A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age.

Vaccine

January 2025

The Child and Adolescent Clinic, Juliane Marie Center, The Danish National University Hospital "Rigshospitalet", Copenhagen, Capital Region of Denmark, Denmark; Institute for Clinical Medicine, University of Copenhagen, Denmark.

Background: Lowering the age for receiving the first dose of a measles-containing vaccine (MCV1) has been suggested to close the emerging immunity gap in infants. However, tolerability remains one of the main concerns for vaccine-hesitant parents. We conducted a systematic review and meta-analysis of reactogenicity following MCV1 in infants under 12 months of age.

View Article and Find Full Text PDF

Vaccination against measles-mumps-rubella and rates of non-targeted infectious disease hospitalisations: Nationwide register-based cohort studies in Denmark, Finland, Norway, and Sweden.

J Infect

January 2025

Bandim Health Project, Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Objectives: To investigate if receipt of measles-mumps-rubella (MMR) vaccine following the third dose of diphtheria-tetanus-acellular pertussis (DTaP3) is associated with reduced rates of non-targeted infectious disease hospitalisations.

Methods: Register based cohort study following 1,397,027 children born in Denmark, Finland, Norway, and Sweden until 2 years of age. Rates of infectious disease hospitalisations with minimum one overnight stay according to time-varying vaccination status were compared using Cox proportional hazards regression analysis with age as the underlying timescale and including multiple covariates.

View Article and Find Full Text PDF

Measles, a highly contagious respiratory illness caused by the measles virus (MeV), poses significant global and national public health challenges despite advancements in vaccination efforts. Though measles was declared eliminated in the United States in 2000, recent years have seen a resurgence of cases, particularly in under-vaccinated communities. This resurgence is compounded by factors such as vaccine hesitancy, the impact of the COVID-19 pandemic on immunization rates, and international travel introducing new cases from endemic regions.

View Article and Find Full Text PDF

Importance: Childhood vaccination rates have declined in recent years; there is also concern that resistance to COVID-19 vaccines could spill over to childhood vaccines.

Objectives: To use local-level data to study trends in childhood vaccination rates and heterogeneity in local rates; including how many areas are below herd-immunity thresholds, and assess the association between COVID-19 vaccine hesitancy and childhood vaccination.

Design: We report, for 11 states with available data, vaccination rates for measles, mumps, rubella (MMR), and diphtheria, tetanus, acellular pertussis (DTaP) vaccines, including percentage of schools/counties with rates ≥95 %, 90-95 %, 80-90 %, and < 80 %.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!